Alphabiz - SK Bioscience has signed a contract to produce vaccine candidate materials for MSD ′Ebola′

This article is translated by AI company Flitto and Alhpa Biz neural machine translation technology

(사진= SK바이오사이언스 제공)

 

[Alpha Biz=(Chicago) Reporter Paul Lee] SK Bioscience consigns next-generation Zaire Ebola vaccine candidate material (CMO) of global healthcare company MSD.

SK Bioscience announced on August 8 that it has signed a new production contract with MSD for the next-generation Zaire Ebola vaccine candidate material.

The MSD is developing a candidate for the next-generation Zaire Ebola vaccine that has improved the process efficiency and thermal stability of the Zaire Ebola vaccine ERVEBO, which is currently in use with the Hilleman Research Institute (Hilleman Laboratories), an international nonprofit research institute. In the future, if the candidate material is successfully developed and approved by regulators, it is expected to contribute to the global supply and accessibility of the Zaire Ebola virus vaccine. The candidate material will be transferred by SK Bioscience and produced at Andong L-House and supplied to international organizations after obtaining approval from related health authorities.

In particular, SK Bioscience plans to expand its consignment development production (CDMO) business with CMO, starting with this contract.

 

Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)